Financial Highlights for the First Nine of the Fiscal Year Ending March 31, 2025
Net sales increased by 2.6% year on year to 460,680 million yen. Operating profit was 5,406 million yen, down 4.5% year on year. Ordinary profit was 6,419 million yen, down 1.3% year on year. The interim net profit attributable to owners of parent was 6,459 million yen, up 27.8% year on year. ・the pharmaceutical wholesale business saw increased sales of products eligible for the price maintenance premium, such as anticancer drugs, and various vaccines, growing sales of influenza test kits and treatments associated with a surge in cases at the end of the year. ・Net income due to the sale of cross-held shares.